Clinical trials: Psychiatric Illness
Major Depressive Disorder
AZD7268 Safety and Tolerability Study
The purpose of this study is to prove the principle that treatment with AZD7268 reduces depressive symptoms in patients with Major Depressive Disorder (MDD) compared with placebo.
- Trial name
- NCT01020799
- Testing
- AZD7268, Escitalopram
- Where
- 17 sites in United States
- Volunteers
- 247 people
- Sponsor
- AstraZeneca
Healthy Smokers
Pilot Pharmacokinetic Study of New Nicotine Lozenge Formulations
The purpose of this study is to determine the pharmacokinetic profile of nicotine following a single oral administration of three new nicotine lozenge formulations (V0474) in comparison with two reference products.
- Trial name
- NCT01574898
- Testing
- V0474 - A mg, V0474 - B mg, V0474 - C mg
- Where
- France
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Pierre Fabre Medicament
Mild Cognitive Impairment, Early Alzheimer's Disease
Development and Evaluation of Computerized Olfactory Training Program for Cognitive Decline in Early Alzheimer's Disease
The purpose of this study is to determine whether daily treatment with this new treatment approach, called COT would be effective in protecting the memory and brain regions of people who are already showing signs of memory loss.
- Conditions
- Mild Cognitive Impairment, Early Alzheimer's Disease, Memory Impairment
- Trial name
- NCT05122598
- Testing
- COT
- Where
- 3 sites in United States
- Volunteers
- 200 people
- Sponsor
- Evon Medics LLC
Anxiety Disorder
GEM 1.5 mg b.i.d. to 4.5 mg b.i.d. Versus Lorazepam in GAD (0777-026)
This study will determine the effectiveness of MK0777 GEM versus Lorazepam in the treatment of patients with generalized anxiety disorder.
- Trial name
- NCT00546624
- Testing
- MK0777
- Volunteers
- 38 people
- Sponsor
- Merck Sharp & Dohme LLC
Postpartum Depression
Efficacy of MI078 Capsules in Treating Postpartum Depression
This study is a multicenter, randomized, double-blind, placebo-controlled trial. It includes three groups. Each group will enroll 24 participants.
- Trial name
- NCT06963580
- Testing
- MI078 capsule dose 1, MI078 capsule dose 2
- Where
- 21 sites in China
- Volunteers
- 72 people
- Sponsor
- Nanjing Minova Pharmaceutical Co., Ltd.
Alzheimer's Disease
Evaluate the Safety and Efficacy of AD-35 Tablet in Subjects With Mild to Moderate Alzheimer's Disease
Brief summary: This is a phase II study to investigate the safety, preliminary efficacy and pharmacokinetics of AD-35 tablet in patients with mild to moderate Alzheimer's Disease.
- Trial name
- WAY (NCT03790982)
- Testing
- AD-35 60 mg
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Zhejiang Hisun Pharmaceutical Co. Ltd.
Alzheimer's Disease
Alzheimer's Disease Long-term Follow-up Study (ALF Study)
Open study for efficacy and safety of donepezil treatment during 48 weeks
- Trial name
- NCT00165724
- Testing
- Donepezil Hydrochloride
- Where
- 7 sites in South Korea
- Volunteers
- 114 people
- Sponsor
- Eisai Korea Inc.
Autism, Autism Spectrum Disorder
Placebo-Controlled Study of Terpenes-Enriched Cannabis Oil T1/C28 for Children With Autism
The goal of this clinical trial is to determine whether cannabidiol (CBD, 28%) combined with terpenes and a small amount of THC (1%) can help reduce symptoms of autism, and to evaluate the safety of this treatment.
- Trial name
- TECA (NCT07199218)
- Testing
- Terpenes-Enriched CBD-Predominant Oil, Terpenes-Enriched CBD Oil (THC-Free)
- Where
- Israel
- Volunteers
- 78 people
- Sponsor
- Bazelet Nehushtan LtD.
Schizophrenia
Open-label Study to Compare Hospitalization Rates of Schizophrenic Patients Treated With Oral Antipsychotics Versus IM Depot Aripiprazole
The purpose of this study is to compare retrospective hospitalization rates of schizophrenic patients treated with oral antipsychotics to prospective hospitalization rates of these patients treated with IM depot aripiprazole.
- Trial name
- ARRIVE US (NCT01432444)
- Testing
- Aripiprazole (Abilify®) IM Depot Injection
- Where
- 124 sites in United States, Canada
- Volunteers
- 493 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia, Schizoaffective Disorder
Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Schizophrenia
This study in patients with schizophrenia is designed to provide preliminary evidence of the safety, tolerability, and pharmacokinetics as well as the effects on cognitive function of 2 doses of EVP-6124 compared with placebo…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Central Nervous System Diseases
- Trial name
- NCT01556763
- Testing
- EVP-6124 (0.3 mg/day), EVP-6124 (1.0 mg/day), Antipsychotic therapy
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- FORUM Pharmaceuticals Inc
Attention Deficit Hyperactivity Disorder (ADHD)
Vayarin® Medical Food Study for Adults With Attention Deficit Hyperactivity Disorder (ADHD)
The primary study objective is to evaluate the efficacy of Vayarin in ADHD adults.
- Trial name
- NCT02257216
- Testing
- Vayarin®
- Where
- 4 sites in United States
- Volunteers
- 171 people
- Sponsor
- Enzymotec
Depression, Bipolar
A Study of Abilify® Tablet(Aripiprazole) as an Adjunctive Treatment in the Bipolar Depression
This is an 8-week, multicenter, randomized, double blind, placebo controlled study to evaluate the efficacy and safety of aripiprazole as an adjunctive treatment with mood stabilizer for the treatment of patients (outpatients or…
- Trial name
- APOLLO (NCT03423680)
- Testing
- Abilify 2, 5, 10, 15mg (Tablet)
- Where
- South Korea
- Volunteers
- 390 people
- Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
Major Depressive Disorder, Depression
Individual Patient Esmethadone (REL-1017) Expanded Access Program
To provide expanded access of esmethadone (REL-1017) to patients with a serious or immediately life-threatening disease or condition that may potentially benefit from esmethadone (REL-1017) who do not have access to other…
- Trial name
- NCT06009003
- Testing
- REL-1017
- Sponsor
- Relmada Therapeutics, Inc.
Schizophrenia
A Trial of 15 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group, 6-week trial to evaluate the efficacy, safety, and tolerability of 2 fixed doses of CVL-231 (Emraclidine) (15 mg QD and 30 mg QD) in…
- Trial name
- NCT05227703
- Testing
- Emraclidine 15 mg, Emraclidine 30 mg
- Where
- 26 sites in United States, Bulgaria and 1 more
- Volunteers
- 391 people
- Sponsor
- AbbVie
Schizophrenia
A Safety and Effectiveness Study of Paliperidone Palmitate in Chinese Patients With Schizophrenia
The purpose of this study will be to evaluate the safety and treatment response of paliperidone palmitate administered to Chinese patients with schizophrenia.
- Trial name
- NCT01947803
- Testing
- Paliperidone Palmitate
- Where
- 12 sites in China
- Volunteers
- 353 people
- Sponsor
- Xian-Janssen Pharmaceutical Ltd.
Opioid-Induced Bowel Dysfunction
Opioid-induced Bowel Dysfunction: Long-Term Assessment of Lubiprostone
The purpose of this study is to evaluate the long-term safety and efficacy of lubiprostone administration in participants with opioid-induced bowel dysfunction.
- Trial name
- NCT00620061
- Testing
- Lubiprostone 24
- Where
- 123 sites in United States, Canada
- Volunteers
- 439 people
- Sponsor
- Sucampo Pharma Americas, LLC
Schizophrenia
A Combination of Two Currently Approved Drugs to Enhance the Treatment of Schizophrenia
Study of a medication for the treatment of Schizophrenia in patients who are already taking Abilify, Risperdal, Seroquel, Zyprexa
- Trial name
- NCT00089869
- Testing
- olanzapine, atomoxetine
- Where
- 20 sites in United States
- Sponsor
- Eli Lilly and Company
Autistic Disorder
An Evaluation of Low Level Laser Light Therapy for Autistic Disorder 2
The purpose of this study is to determine whether the Erchonia HLS Laser is effective in the treatment of irritability associated with autistic disorder in children and adolescents aged five (5) to twelve (12) years.
- Trial name
- NCT04895605
- Testing
- Erchonia HLS Laser
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Erchonia Corporation
Alzheimer's Disease
Clinical Safety and Efficacy Evaluation of NanoLithium® NP03 in Patients With Mild-to-severe Alzheimer's Disease
This proof-of-concept study will assess safety, tolerance, and efficacy of NanoLithium® NP03 in patients with mild-to-severe Alzheimer's Disease (AD).
- Trial name
- NanoLi®_AD (NCT05423522)
- Testing
- NanoLithium® NP03
- Where
- 8 sites in France
- Volunteers
- 72 people
- Sponsor
- Medesis Pharma SA
Erectile Dysfunction
Research Evaluating an Investigational Medication for Erectile Dysfunction - General ED
This study is being conducted to compare the safety and efficacy of 3 doses of avanafil to placebo in men with mild to severe erectile dysfunction.
- Trial name
- REVIVE (NCT00790751)
- Testing
- avanafil
- Where
- 41 sites in United States
- Volunteers
- 646 people
- Sponsor
- VIVUS LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.